Your session is about to expire
Cymbalta vs Viibryd
Introduction
For patients dealing with major depressive disorder (MDD) or other forms of depression, certain medications that modify the levels of mood-related compounds in the brain, known as neurotransmitters, can assist in stabilizing depressive lows and managing symptoms. Cymbalta and Viibryd are two such medications commonly prescribed for depression. They each influence different neurotransmitters in the brain but both help stabilize moods in patients suffering from depression. Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI), impacting levels of both serotonin and norepinephrine. On the other hand, Viibryd is classified as a selective serotonin reuptake inhibitor (SSRI) and partial serotonin receptor agonist affecting primarily levels of serotonin.
What is Cymbalta?
Duloxetine (the generic name for Cymbalta) is an antidepressant that belongs to a class of drugs known as serotonin-norepinephrine reuptake inhibitors (SNRIs). First approved by the FDA in 2004, Duloxetine increases levels of serotonin and norepinephrine by inhibiting their reabsorption into cells in the brain. This boosts mood and helps alleviate depression. It's prescribed for several conditions including major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic peripheral neuropathy, and chronic musculoskeletal pain.
Vilazodone (Viibryd), on the other hand, is categorized as an SSRI and 5-HT1A receptor partial agonist. Approved by the FDA in 2011, it also enhances serotonin levels but through a slightly different mechanism - it not only prevents serotonin reabsorption but also binds to one type of serotonin receptor (5-HT1A) which may aid its therapeutic effect against depression.
Both medications are effective at treating depression; however, they have distinct side effects profiles due to their differences in chemical structure and mode of action. As always with medication choices like these ones should consult with their healthcare provider.
What conditions is Cymbalta approved to treat?
Cymbalta has been approved for the treatment of various conditions including:
- Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Diabetic Peripheral Neuropathic Pain
- Fibromyalgia
- Chronic Musculoskeletal Pain
How does Cymbalta help with these illnesses?
Cymbalta, also known as Duloxetine, is an antidepressant that works by increasing the levels of serotonin and norepinephrine in the brain's synapses. It does this by inhibiting their reabsorption into neurons which allows these neurotransmitters to remain active for a longer period. Serotonin plays an important role in mood balance while norepinephrine affects concentration and alertness. It is believed that people suffering from depression have lower levels of these chemicals; hence, by increasing their availability, Cymbalta helps mitigate depressive symptoms and stabilize moods.
On the other hand, Viibryd (Vilazodone) functions similarly but with a unique twist: it not only prevents serotonin reuptake but also partially stimulates serotonin receptors thereby enhancing its activity. This dual mechanism could potentially provide more effective relief for certain individuals dealing with depression compared to other standard selective serotonin reuptake inhibitors (SSRIs). However, everyone has different responses to medications so what works best will depend on the individual patient's condition, tolerance to side effects, and response to treatment.
What is Viibryd?
Viibryd, also known by its generic name vilazodone, is a selective serotonin reuptake inhibitor (SSRI) and partial 5-HT1A receptor agonist. This dual mechanism of action means it not only increases the levels of serotonin in the brain by reducing their reabsorption but also stimulates serotonin production at specific receptors. Viibryd was first approved by the FDA in 2011 for treating major depressive disorder. Because it has a different pharmacological profile from other SSRIs like Cymbalta, its side-effect profile can vary as well. Unlike many SSRI antidepressants such as Cymbalta which can often lead to sexual dysfunction and weight gain, Viibryd is less likely to cause these particular side effects due to its unique interaction with certain serotonin receptors. Additionally, because Viibryd affects both the absorption and stimulation of serotonin, it may benefit patients who have not responded optimally to "typical" SSRIs or SNRIs such as Cymbalta.
What conditions is Viibryd approved to treat?
Viibryd is a novel antidepressant that has been approved by the FDA for use in treating conditions such as:
- Major depressive disorder (MDD), which is a severe form of depression that can interfere with daily activities and relationships.
- Mixed anxiety-depressive disorder, where patients experience symptoms of both anxiety and depression.
How does Viibryd help with these illnesses?
Serotonin is a neurotransmitter that plays significant roles in many processes within the body, including mood regulation, sleep, and digestion. Reduced levels of serotonin have been linked to depression. Viibryd works by increasing available serotonin in the brain, thereby potentially alleviating symptoms of depression. Unlike Cymbalta which increases both serotonin and norepinephrine levels (thus classified as an SNRI), Viibryd belongs to a unique class of drugs known as SSRI's (Selective Serotonin Reuptake Inhibitors) with a partial agonist at 5-HT1A receptors, this combination helps to enhance its antidepressant effect without significantly affecting norepinephrine or dopamine pathways. This makes it an attractive choice for patients who may not respond favorably to typical SSRI's or SNRIs like Cymbalta, or those who experience unpleasant side effects from them.
How effective are both Cymbalta and Viibryd?
Both duloxetine (Cymbalta) and vilazodone (Viibryd) have established histories of success in treating patients with depression, and they were initially approved by the FDA only 9 years apart. Since they act on different neurotransmitters, they may be prescribed under different circumstances. The effectiveness of duloxetine and vilazodone in alleviating depression was directly studied in a double-blind clinical trial in 2012; both drugs exhibited similar efficacy in managing symptoms of depression as well as similar, promising safety profiles. In this study, none of the different metrics that measured efficacy for treating depression differed between patients receiving vilazodone or those receiving duloxetine.
A 2006 review demonstrated that Cymbalta is effective at easing chronic pain from conditions such as fibromyalgia and nerve damage due to diabetes starting from the first week of treatment, along with its side effect profile being generally favorable over many other antidepressants. Besides helping treat major depressive disorder and generalized anxiety disorder, it also appears to reduce musculoskeletal pain.
On the other hand, a meta-analysis conducted in 2015 indicated that Viibryd seems to be more effective than placebo for treating depression while peaking at a dose around 40 mg/day. Nonetheless, Viibryd is commonly considered after SSRIs or SNRIs like Cymbalta have already been tried due to less robust data confirming its stand-alone efficacy compared to these medications. However, because Viibryd has fewer sexual side effects than many antidepressants including Cymbalta – which can lead reduced libido – it might be optimal for patients who experience these adverse reactions.
At what dose is Cymbalta typically prescribed?
Oral dosages of Cymbalta range from 20–60 mg/day, but research suggests that starting with a dosage of 30-60 mg/day is typically effective for treating major depressive disorder and generalized anxiety disorder in most adults. For some conditions such as chronic musculoskeletal pain, the dose may be increased up to 120mg/day if there is no response after a few weeks. However, it's important not to exceed the maximum recommended dosage by your healthcare provider. On the other hand, Viibryd should be started at an initial dose of 10 mg/day for seven days, then increased to 20 mg/day for subsequent seven days. The dose can further be increased up to a maximum of 40mg per day based on individual patient response and tolerability. As always, changes in dosing regimen should only be made under direct supervision from your healthcare provider.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Viibryd typically prescribed?
Viibryd treatment usually begins with a starting dose of 10 mg/day. This can then be increased to 20 mg/day after one week, taken as a single daily dose. The optimal dosage is typically 40mg/day, which should be reached by the end of the second week of treatment if tolerated well by the patient. However, it's important to note that some patients may not experience full therapeutic effects until they've been on Viibryd for several weeks at this highest recommended dosage. Always remember that it's crucial to follow your healthcare provider’s instructions when adjusting medication dosages.
What are the most common side effects for Cymbalta?
When using Cymbalta or Viibryd, patients may experience a variety of side effects:
- Nervousness
- Restlessness and insomnia
- Fatigue (general weakness and tiredness)
- Tremors or shaking involuntarily
- Loss of appetite
- Nausea and indigestion (discomfort in the upper abdomen)
- Diarrhea
- Dry mouth
- Reduced libido (decreased interest in sexual activity)
- Abnormal ejaculation or orgasm problems
- Sweating excessively
-Unusual dreams
-An increased risk for catching colds or flu-like symptoms
-Sore throat
-Inflammation of nasal passages leading to sinus pressure
-Yawning excessively.
Please consult with your healthcare professional if these side effects become problematic.
Are there any potential serious side effects for Cymbalta?
While both Cymbalta and Viibryd are prescribed for depression, they come with their own set of risks.
With Cymbalta, some patients may experience heightened thoughts about suicide or self-harm, especially those under 24 years old. Signs of severe allergic reactions such as hives, difficulty breathing, swelling in the face or throat can also occur. Other serious side effects include blurred vision or eye pain; rapid heartbeats; feeling faint; low sodium levels - indicated by headaches, confusion, slurred speech and loss of coordination; severe nervous system reaction including rigid muscles and tremors.
Viibryd carries similar risks but it's known to cause a potentially life-threatening condition called serotonin syndrome if interacted with certain drugs. Symptoms include agitation, hallucinations, fever sweating shivering fast heart rate muscle stiffness twitching loss of coordination nausea vomiting diarrhea. If you notice any signs of these conditions while on either medication consult your doctor immediately.
What are the most common side effects for Viibryd?
When considering Viibryd, some of its potential side effects may encompass:
- Nausea or vomiting
- Diarrhea or constipation
- Dry mouth
- Sleep problems (insomnia)
- Feeling anxious, restless, or nervous
- Weight changes, possible weight loss
- Increased sweating
- Reduced sexual desire or ability Remember that these are potential side effects and not everyone experiences them. It's also important to discuss with your healthcare provider about any concerns you might have regarding this medication.
Are there any potential serious side effects for Viibryd?
While Viibryd is generally well-tolerated, it can cause some serious side effects in rare cases. Be sure to seek immediate medical attention if you experience:
- Signs of an allergic reaction such as skin rash, itching or hives; difficulty breathing; swelling of the face, lips, tongue or other parts of the body
- Elevated risk of suicidal thoughts and behaviors particularly among children, adolescents and young adults
- Unusual changes in mood or behavior including anxiety, agitation or panic attacks
- Serotonin syndrome symptoms like agitation, hallucinations (seeing things that aren't there), confusion, rapid heartbeat, high body temperature above 38°C (100.4°F), lack of coordination
- Visual disturbances such as blurred vision or eye pain
- Irregular heartbeats which may feel fast-paced or uneven
- Symptoms related to mania like racing thoughts; unusually elevated mood; excessive energy; reduced need for sleep; excessive talking. If any of these occur while taking Viibryd , immediately contact your healthcare provider for guidance.
Contraindications for Cymbalta and Viibryd?
Both Cymbalta and Viibryd, like many other antidepressant medications, may exacerbate symptoms of depression in some individuals. If you observe a worsening of your depression or an escalation in suicidal thoughts or behavior, please seek immediate medical attention.
Neither Cymbalta nor Viibryd should be taken if you are using, or have recently used monoamine oxidase (MAO) inhibitors. Always inform your healthcare provider about any medications you're currently taking; MAOIs will require a period of about 2 weeks to clear from the system before starting either Cymbalta or Viibryd to prevent potentially dangerous interactions.
How much do Cymbalta and Viibryd cost?
For the brand name versions of these drugs:
- The price of 30 capsules of Cymbalta (60 mg) averages around $250, which works out to about $8.33/day.
- The cost of Viibryd is notably higher - a pack of 30 tablets (40 mg) costs approximately $350, working out to roughly $11.67/day.
Thus, if you are taking the maximum recommended dosage for each drug (i.e., 60 mg/day for Cymbalta and 40mg/day for Viibryd), then on a per-day treatment basis, brand-name Cymbalta would be less expensive than Viibryd. However, it's crucial to remember that cost should not be your primary consideration when choosing between these two medications.
As for their generic versions:
- Duloxetine (generic version of Cymbalta) comes in packs ranging from 20 to 500 capsules with an approximate cost starting as low as $0.15 per day if purchasing larger quantities upfront and never exceeding about $2/day.
- Vilazodone Hydrochloride (generic version of Viibryd), available in similar quantities can have a price point somewhere around $.50-$1 per day depending on the purchase quantity.
The prices vary significantly based on location, exact dosage prescribed by your healthcare provider and any insurance coverage you may have.
Popularity of Cymbalta and Viibryd
Duloxetine, available in generic form and under brand names such as Cymbalta, was prescribed to about 10.3 million people in the US in 2020. Duloxetine accounted for approximately 16% of SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) prescriptions in the US that year. It has been consistently popular since its introduction and is used not only to treat depression but also generalized anxiety disorder, fibromyalgia and neuropathic pain.
Vilazodone or Viibryd, a relatively newer antidepressant classified as an SSRI and partial serotonin receptor agonist, was prescribed to around 800 thousand people during the same period. While it has shown effectiveness for treating major depressive disorder with fewer sexual side effects compared to other SSRIs, its overall usage remains lower than duloxetine's due largely to being on the market for less time. The prevalence of Vilazodone has been gradually increasing since its approval by FDA in 2011.
Conclusion
Both Cymbalta (duloxetine) and Viibryd (vilazodone) have a strong presence in the treatment of depression, with numerous clinical studies supporting their effectiveness over placebo treatments. In certain scenarios, these drugs may be used together, but this should only be done under rigorous medical supervision due to potential interactions between them. Their mechanisms of action differ: Cymbalta primarily works on serotonin and norepinephrine reuptake inhibition, while Viibryd acts as a serotonin receptor agonist as well as inhibiting its reuptake.
Cymbalta is often considered first line of treatment for depression and also for diabetic peripheral neuropathy or fibromyalgia. On the other hand, Viibryd is typically prescribed if patients have not responded adequately to initial SSRI/SNRI antidepressants or want to avoid some common side-effects associated with these medicines like sexual dysfunction.
Generic versions are available for both drugs which can significantly reduce costs especially for those paying out-of-pocket. It's important to remember that with Cymbalta and Viibryd there might be an adjustment period where effects aren't immediately noticeable.
The two medications share similar side effect profiles; they're generally well-tolerated but unwanted effects such as nausea, dry mouth or dizziness could occur. Notably, sexual side effects are less likely with Viibryd compared to other SSRIs/SNRIs including Cymbalta. Patients must monitor their mood closely when starting either medication and seek immediate medical attention if symptoms worsen or suicidal thoughts emerge.